GGrantIndex
← Search

Protocol Review and Monitoring System

$204,363P30FY2024CANIH

Beckman Research Institute/City Of Hope, Duarte CA

Investigators

Linked publications & trials

Trial NCT07664670Trial NCT07664579Trial NCT07650656Trial NCT07628894Trial NCT07619599Trial NCT07612085Trial NCT07611370Trial NCT07608627Trial NCT07608458Trial NCT07608445Trial NCT07595874Trial NCT07590583Trial NCT07583810Trial NCT07583303Trial NCT07582172Trial NCT07582159Trial NCT07578077Trial NCT07578025Trial NCT07544992Trial NCT07365306Trial NCT07363408Trial NCT07293403Trial NCT07288034Trial NCT07278856Trial NCT07275216Trial NCT07271355Trial NCT07235501Trial NCT07226544Trial NCT07226102Trial NCT07225855Trial NCT07225738Trial NCT07220447Trial NCT07219147Trial NCT07218913Trial NCT07218718Trial NCT07218692Trial NCT07218510Trial NCT07210086Trial NCT07202247Trial NCT07184294Trial NCT07136493Trial NCT07133997Trial NCT07128680Trial NCT07126301Trial NCT07125729Trial NCT07042438Trial NCT07040982Trial NCT07037004Trial NCT07025564Trial NCT07025538Trial NCT07020533Trial NCT07003100Trial NCT06996119Trial NCT06985784Trial NCT06954831Trial NCT06922604Trial NCT06918431Trial NCT06910761Trial NCT06860815Trial NCT06859008Trial NCT06834126Trial NCT06815029Trial NCT06815003Trial NCT06780787Trial NCT06763341Trial NCT06763328Trial NCT06735690Trial NCT06735664Trial NCT06731894Trial NCT06675136Trial NCT06675123Trial NCT06672224Trial NCT06626256Trial NCT06625619Trial NCT06581211Trial NCT06580015Trial NCT06575725Trial NCT06575686Trial NCT06575296Trial NCT06572631Trial NCT06572618Trial NCT06572605Trial NCT06549478Trial NCT06543381Trial NCT06538389Trial NCT06500377Trial NCT06498973Trial NCT06454409Trial NCT06454383Trial NCT06453044Trial NCT06447987Trial NCT06440850Trial NCT06408220Trial NCT06399419Trial NCT06328621Trial NCT06287944Trial NCT06260033Trial NCT06249282Trial NCT06196008Trial NCT06195891

Abstract

Abstract Protocol Review and Monitoring System The City of Hope Comprehensive Cancer Center (COHCCC) Protocol Review and Monitoring System (PRMS) has developed a two-stage review system for the review, oversight and support of cancer research conducted by its investigators. This review system includes a first stage review by (1) Multidisciplinary Disease and Modality Teams (DT/MT) for concept review and endorsements; followed by a second stage review by (2) the Protocol Review and Monitoring Committees (PRMC) which include the Cancer Protocol Review & Monitoring Committee (CPRMC) and the Biospecimen and Data Review Committee (BDRC). The offices that administratively support the DT/MT and the PRMC are within the Clinical Trials Office (CTO) and Clinical Research Protections (CRP) Office, respectively. During its first and second stage reviews, the PRMS is focused on the scientific merit of protocols, prioritization and feasibility of trial completions, as well as the oversight of the progress of approved research and termination of any research that no longer meets those criteria. All proposed cancer clinical research must initially be endorsed by a multi-disciplinary DT/MT and reviewed and approved by the PRMC and reviewed by the PRMC for scientific progress on at least an annual basis. The PRMC has the authority to close trials that do not demonstrate scientific progress and appeals are evaluated by the Committee. The BDRC was launched in April 2021 to support an enterprise-wide, efficient, and centralized scientific, prioritization, and feasibility review process for research involving only the use of tissue and/or data. The BDRC follows the same review processes as the CPRMC and first stage review is required. The PRMS received full approval from the National Cancer Institute (NCI) in 2017.

View original record on NIH RePORTER →